Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BMS-986277 |
Synonyms | |
Therapy Description |
Limited information is currently available on BMS-986277, a putative oncolytic adenovirus expressing CD80 that is selective for epithelial cells (Apr 2023). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BMS-986277 | BMS 986277|BMS986277 | Limited information is currently available on BMS-986277, a putative oncolytic adenovirus expressing CD80 that is selective for epithelial cells (Apr 2023). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03363776 | Phase Ib/II | BMS-986277 BMS-986277 + Nivolumab | An Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers | Terminated | USA | CAN | 0 |